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Abstract
Male breast cancer (MBC) is rare, and research on the predictors of MBC has been
limited because of inadequate funding in and outside of the United States. One goal of
this study was to eradicate the stereotyping of breast cancer as a female disease. The
emergence of medical technology and education to benefit the public will help to ensure
greater health awareness at the individual, community, and global levels. The purpose of
this study was to understand the influence of the predictors of age; race (Black, White,
and Other); and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. The
study was guided by the social determinants of health model. A quantitative approach
was used to analyze archival data from 2011 to 2013 in the Surveillance Epidemiology
and End Results (SEER) database using SPSS v.23. Data from 427 MBC patients ages 18
years and older from the United States comprised the sample. The SEER data were
analyzed using logistic regression analysis. Results showed that of the 427 cases of MBC
that were analyzed, 55 had a diagnosis of Grade I, 190 had a diagnosis of Grade II, and
182 had a diagnosis of Grade III. For 3 years, 116 men had undergone mastectomy.
Grade I cancer, Grade II cancer, and Grade III cancer were statistically insignificant
predictors of mastectomy; however, age, race was a statistically significant predictor of
mastectomy among White men with MBC. The results will contribute to social change
initiatives by educating the public about the predictors of mastectomy in MBC patients.
The results also will increase the current knowledge base by informing the public, clinical
professionals, and patients about the relationship of the predictors of age; race; and grade
of cancer (I, II, or III) on the outcome of mastectomy in MBC.
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Chapter 1: Introduction to the Study
Introduction
Male breast cancer (MBC) occurs infrequently, and research focusing on MBC
has been limited because of inadequate funding within and outside the United States
(Chavez-MacGregor, Clarke, Lichtensztajn, Hortobagyi, & Giordano, 2013; Kornegoor
et al., 2012). The incidence of MBC is rising, and men across the globe are continuing to
die from MBC. Chapter 1 introduces the topic, provides background information about
MBC, and includes a statement of the problem. The purpose of the study and the
theoretical/conceptual framework and nature of the study are defined, and the limitations
and delimitations of the study are examined. In addition, the chapter includes the
assumptions, scope, and significance of the study. The research questions (RQs) are
provided, and a summary concludes the chapter. The purpose of this study was to
understand the influence of the predictors of age; race; and grade of cancer (I, II, or III)
on the outcome of mastectomy in MBC. The results will contribute to the literature and
will support social change initiatives by educating the public about the predictors of
mastectomy in MBC patients.
Background
MBC is an uncommon disease whose occurrence often is overlooked, thus leading
to more advanced stages (American Cancer Society [ACS], 2012). Because of the late
diagnosis and known rarity of MBC, one could argue that exploring the predictors of it is
not crucial, despite the number of men dying from MBC (Sandhu et al., 2012). A man’s
risk of developing breast cancer in his lifetime is about one in 1,000 (ACS, 2012).
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According to the National Cancer Institute (NCI, 2016a), approximately 249,260
new cases of female breast cancer and 2,600 new cases of MBC occur annually in the
United States. The NCI (2016b) estimated that in 2016, 440 men would die from the
disease in the United States and that in Texas alone, 132 men would be diagnosed with
MBC in that same year, with 28 of them dying from the disease. In the United Kingdom,
about 240 men are diagnosed with MBC annually (Kipling, Ralph, & Callanan, 2014).
Globally, research has shown that the incidence of MBC is higher in several regions of
Africa; for example, Zambia has a rate of 15%, and Egypt and Tanzania have rates of
6%, respectively (“Male Breast Cancer Numbers Rising Most Fail to Spot It Until It Has
Spread to Lymph Nodes,” 2004).
Role of Society and Acceptance of MBC
Social change plays a vital role in encouraging men to undergo the same annual
mammogram screening that women have been supporting for years. Like women, men
need to be screened, diagnosed, and treated to reduce the morbidity and mortality rates of
the disease (Centers for Disease Control and Prevention [CDC], 2012b); Fentiman,
Fourquet, & Hortobagyi, 2006; National Institutes of Health [NIH], 2013; NCI, 2013).
According to Robinson, Metoyer, and Bhayani (2008), breast cancer has always been
seen as a disease of women in general. Most cases of MBC occur among men between
the ages of 60 and 70 years (Cutuli, 2009); however, younger men are now being
diagnosed with MBC (Fentiman et al., 2006; NIH, 2013; Rachid, Yacouba, & Hassane,
2009). Robinson et al. stated that serious issues remain because of the lack of studies
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focusing on MBC. They asserted that the gap in knowledge about MBC highlights the
need for further studies on the impact of this disease on men.
Brain, Williams, Iredale, France, and Gray (2006) stated that acceptance of the
disease by men is impeded by the stigma of coping with the disease, altered body image,
and the unavailability of supportive needs. Robinson et al. (2008) added anxiety and
depression symptoms to the list. The most significant factor upsetting self-esteem is body
image (Brain et al., 2006; Burson et al., 2009; Hiatt & Breen, 2008; Rosenbaum et al.,
2004). Individuals in marital relationships might experience distress manifesting as
decreased satisfaction in terms of intimacy, sexual function, and appreciation of spouse or
partner (Brain et al., 2006).
Ahmed, Ukwenya, Abdullahi, and Muhammad (2012) stated that MBC might be
an exceptional condition representing about 1% of all breast cancers. Ahmed et al.
evaluated male patients who had a histological diagnosis of breast cancer from 2001 to
2010. Modified radical mastectomies were performed on those patients after the
evaluations (Ahmed et al., 2012).
Mathew, Perkins, Stephens, Middleton, and Yang (2008) explained that MBC
appears on a mammogram often as a spiculated margin, a noncalcified high-thickness
mass with an asymmetrical figure located in a subareolar area. It is characterized on a
sonogram as a hard hypoechoic group and a microlobulated border (Mathew et al., 2008).
The earliest stages of cancer are referred to as carcinoma in situ (Mathew et al., 2008).
The finding of this particular cancer in the breast milk duct is called ductal carcinoma in
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situ, or DCIS, typical in men because of the lack of early screening or early detection
(Doyle, Steel, & Porter, 2011).
Staging of MBC
Members of the health care team initiate staging to determine disease progression
once there is evidence of a malignant tumor or a diagnosis of breast cancer (NCI, 2013).
Staging of breast cancer depends on the size of the tumor, the number and location of any
lymph nodes involved, and whether there has been an effect on other organs, and
according to the NCI (2013), cancer can be categorized as one of four stages:
•

Stage 0-I: Early detection; cancer cells are confined to a limited area.

•

Stage II: Cancer cells begin to spread around the breast area.

•

Stage III: Cancer cells invade neighboring tissues near the breast.

•

Stage IV: Cancer cells have metastasized to other organs of the body and are
usually invasive.

Universally, tumors are graded as I, II, III, or IV, depending on the rate of
abnormality. The NCI (2013) described the stages as the following:
•

GX: Grade cannot be assessed (undetermined grade).

•

GI: Well differentiated (low grade); appears close to normal.

•

GII: Moderately differentiated (intermediate grade); abnormal cells spread
slowly.

•

GIII: Poorly differentiated (high grade); abnormal cells grow rapidly with less
aggressive spread.
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•

GIV: Undifferentiated (high grade); grow rapidly and spread faster (NCI,
2013).

Staging of MBC is crucial because proper assessment of the disease can facilitate
its early diagnosis and detection, and slow its progress from Stage 0 to more advanced
stages (CDC, 2012b; Chavez-MacGregor et al., 2013; Ginossar, 2008; National Breast
Cancer Awareness Month, 2010; NCI, 2013). Kanthan, Fried, Rueckl, Senger, and
Kanthan (2010) stated that MBC can impact all segments of the male population,
regardless of socioeconomic (SES) class and age. MBC is a rare yet potentially
destructive disease with little known risk factors (Kanthan et al., 2010).
Proper assessment and staging, along with early diagnosis and detection, can slow
the progress of MBC to later stages of the disease (Ginossar, 2008). MBC usually
presents with a palpable, unilateral, and painless subareolar mass (Fentiman et al., 2006)
that often is located away from the nipple (Doyle et al., 2011; Fentiman et al., 2006; NIH,
2013). Twenty-nine percent of MBC patients diagnosed with invasive ductal cancer
undergo surgery (“Breast,” 2013). Seventeen percent of other MBC patients discovered
with tumors, particularly unadulterated DCIS, have surgery (Vetto, 2010). The causes of
MBC are still being investigated, but awareness continues to evolve, and diagnoses have
become much more rapid (Brain et al., 2006).
Role of Different Factors in Breast Cancer Development
Both biological influences and genetic (inherited) factors play a significant role in
the development of breast cancer (Mathew et al., 2008). Certain inherited gene mutations
might be passed from parents to their children. BRCA1 and BRCA2 are the best known
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genes associated with breast cancer (Rossman, Libjegren, & Bergh, 2007). Most MBC
cases can be traced back to relatives who carried BRCA2 gene mutations (Kreiter,
Richardson, Potter, & Yasui, 2014; Mathew et al., 2008). However, Carter et al. (1998)
reported that 54 MBC participants in their study were lacking BRCA gene mutations; two
participants had the BRCA2 mutation not related to family, and five had BRCA2
mutations pointing to first-degree relatives with breast cancer. Carter et al. showed that
exposure to electromagnetic fields also might have been a contributing factor to MBC.
Another high risk associated with MBC is hyperestrogenization resulting from
Klinefelter’s, gonadal dysfunction, obesity, drinking alcohol, and exposure to radiation,
whereas gynecomastia remains inconclusive (Carter et al., 1998; Fentiman et al., 2006).
Detection of MBC
Through tertiary means, men are detected at a later stage of breast cancer than
women are (Robinson et al., 2008). Almost 2,000 new cases are diagnosed each year, and
as many as 450 deaths are attributed in contrast to women with breast cancer (ACS,
2016). Brain et al. (2006) studied the distress associated with MBC and reported that 161
men with breast cancer who completed a questionnaire shared the same symptoms with
women in terms of anxiety, depression, cancer-specific distress, and body image.
Because of the gap in knowledge of MBC, I conducted this study to increase awareness
about the predictors of mastectomy in MBC patients.
Problem Statement
The ACS (2016) stated that cancer places a heavy burden on the public health
care system. Cancer comprises various categories of diseases affecting different parts of
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the body (Fentiman et al., 2006; NCI, 2013; NIH, 2013). The incidence of MBC in the
United States over the past 30 years has risen from 0.86% to 1.2% per 1 in 100,000 men
and constantly continues to be discovered (Fentiman et al., 2006; Grenader, Goldberg, &
Shavit 2008; Klein, Ji, Rea, & Stoodt, 2011; Spiers & Shaaban, 2008). MBC often results
in mastectomy, but there has been minimal research on MBC and the predictors of
mastectomy. I undertook this quantitative study using secondary data from 2011 to 2013
in the Surveillance Epidemiology and End Result (SEER) database to broaden knowledge
of the predictors of mastectomy in MBC.
Men diagnosed with breast cancer often are in an advanced stage of the disease
because of the lack of awareness, timely detection, and management strategies
(Contractor, Kaur, Rodrigues, Kulkarni, & Singhal, 2008; Fentiman et al., 2006; Klein et
al., 2011). Cancer is the second leading cause of death in men in the United States
(Fentiman et al., 2006; Field, Campbell, & DeBoer, 2008; Hiatt & Breen, 2008; NCI,
2013; NIH, 2013). Unlike cancer of the female breast, MBC is not yet fully understood
(Brain et al., 2006). Knowledge and technology continue to evolve to find a cure, and
diagnostics make it easier to discover abnormalities; however, ecological influences and
genetic (inherited) factors play a role in the development of cancer (Brain et al., 2006).
Most breast lumps in men usually are the result of gynecomastia, the noncancerous
growth of breast tissue (Brain et al., 2006).
Purpose of the Study
The purpose of this study was to understand the influence of the predictors of age;
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. Vast
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research has been conducted on breast cancer in general, but the majority of investigative
work has focused on the female population, with minimal attention directed toward
MBC. This quantitative study helps to expand knowledge of MBC, particularly the
influence of specific predictors of mastectomy.
Research Questions and Hypotheses
The analysis of secondary data required the application of theoretical
understandings and conceptual skills to address the three RQs that guided this study:
RQ1: How will age impact knowledge related to mastectomy in MBC?
H01: Age will not relate to mastectomy in MBC.
Ha1: Age will relate to mastectomy in MBC.
RQ2: How will race account for MBC in relation to mastectomy?
H02: Race does not account for MBC in relation to mastectomy.
Ha2: Race does account for MBC in relation to mastectomy.
RQ3: Is there a predictive relationship between mastectomy and Grade I, II, or III
cancer in MBC?
H03: There is no predictive relationship between mastectomy and Grade I, II, or
III cancer in MBC.
Ha3: There is predictive relationship with mastectomy and Grade I, II, or III
cancer in MBC.
The RQs were analyzed using simple binary logistic regression analysis.
Modeling included all risk factors listed above in addition to all demographic variables.
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The independent variables (IVs) were age; race; and grade of cancer (I, II, or III). The
dependent variable (DV) was mastectomy.
Theoretical Framework
Social determinants of health refer to the conditions in which people are born,
grow, live, work, and age (World Health Organization [WHO], 2013). These social
determinants are shaped by the distribution of money, power, and resources at global,
national, and local levels. The social determinants framework (see Figure 1) was
designed to aid in understanding how these factors interact with other factors in the
causation of MBC (NCI, 2013; NIH, 2013). The framework began from the perspective
of a disease-free state through preclinical and early cancer detection to Grades I, II, and
III; diagnosis; survivorship; and death (NCI, 2013). Social conditions and policies, access
to health care, social/psychological predictor factors, and the biological mechanism of
carcinogenesis are all part of the social determinants framework (Hiatt & Breen, 2008).
Policies and legislation pertaining health care coverage in terms of care of illness shaped
individual behaviors and the use of clinical services regarding the early detection of
disease (NCI, 2013). Investigators working in all areas of cancer investigation have faced
difficulties navigating the constructs in the framework (Hiatt & Breen, 2008; NCI, 2013).
Social determinants of health are explained to showcase improvements in the
standard of living and sanitary reform during the 19th and 20th centuries (Scambler, 2003).
The health of a population is closely tied to physical, social, and economic environments;
psychophysiology and emotional states are related to physiological change and disease
(Scambler, 2003). Understanding the causes of health is part of public health thinking;
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Pioneers in public health recognized the importance of the social determinants in
achieving better population health (Scambler, 2003).
I used the social determinants of health framework to understand how social
determinants interact with other factors to investigate MBC and to acknowledge changes
that occur in its discovery (NCI, 2013; NIH, 2013). The framework starts with the cancer
series and adds levels of analysis and then considers the impact of interventions in the
management of MBC (Hiatt & Breen, 2008; NCI, 2013; NIH, 2013). The social aspects
of the disease resulting from the complex interactions of the risk factors of economic
support; psychosocial risks; social, environmental, and behavioral causation; genetic
factors; and health services are implicated in more than the disease. Modification of these
risk factors could prevent MBC.
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Figure 1. Social determinants of health framework.
Adapted from WHO (2013). Social determinants of health. Retrieved from http://www.who.int/

Health Care Systems
The health care system is one social determinant of health that is responsible for
health disparities in health status (WHO, 2013). In the social determinants of health
framework, achieving health equity is possible “when everyone has the opportunity to
‘attain their full health potential’ and no one is ‘disadvantaged from achieving this
potential because of their social position or other socially determined circumstance”
(CDC, 2012a). Access to health care has been restricted because of poverty, lack of
education, stigma, and racism, all of which are factors contributing to health inequities
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(CDC, 2012a). The CDC (2012a) argued that Whites have better access to the health care
system than Blacks and members of other races do because they have health insurance.
Access to health care. The social determinants of health framework views cancer
from a disease-free status through the preclinical early grades (Grades I, II and III;
survivorship; and death (NCI, 2013). Restricted access to health care, high medical costs,
and lack of insurance coverage have led to unmet health care needs, one of which is early
screening to prevent development of the later stages of MBC. All of these conditions
have impacted the decision of men to receive treatment or mastectomy (Healthy People
2020, 2016). The framework also affects social conditions and policies that can shape
individual behaviors and the use of clinical services for early detection of disease (NCI,
2013).
Health inequities can be reduced in several ways: They can (a) provide programs
for disadvantaged populations; (b) bridge the gap between underserved and better served
populations; (c) provide access to health care in rural areas without discrimination in
terms of gender for MBC oncology clinics (WHO, 2013); and (d) ensure equal treatment
or care for underinsured populations, particularly MBC patients.
Behavioral and Psychological Risk Factors
Psychosocial risk factors. A social network is a strong communication strategy
in reaching communities. Social and family support systems were linked to the
framework of this research. Psychosocial predictor variables that served as risk factors
caused by Grade I, Grade II, or Grade III MBC led me to consider mastectomy the DV in
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the study. The latter resulted in the following social determinant constructs of anxiety,
depressive symptoms, distress, body image, coping mechanisms, and emotional support.
These factors encourage healthy choices and lifestyles that are the main
influences on the health, knowledge, behaviors, and skills that people use to cope with
demanding life issues and circumstances (Healthy People 2020, 2016). Social support
includes practical assistance; financial help; and the availability of information, advice,
and psychological support (Locker, 1994). The effects of practical and emotional support
also have been studied. According to Lyyra and Heikkinen (2006), men lacking
emotional support were 2.5 times higher than those who had emotional support to not
agree to undergoing mastectomy. Ostberg and Lennartson (2007) reported that
individuals who have diverse source of support have better health outcomes.
Social, environmental, and behavioral causation. Social and physical
environments, such as those that carry chemical toxins and pollutants associated with
industrial development, influence health. Risk conditions are integral to those
environments, and they can damage health directly. Improving environmental health
requires political intervention and personal behavioral changes (Healthy People 2020,
2016). Behavioral factors that can determine health status include proper nutrition,
sufficient physical activity, and reductions in habits such as tobacco and alcohol usage
(Locker, 1994).
Biological and Genetic Factors
Biological and genetic factors impact health and well-being, and they are linked
to the health system (WHO, 2013). People whose parents have illnesses such as diabetes,
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cancer, and high blood pressure are predisposed to also having to deal with these
conditions. Biology plays a dominant role in the health and well-being of everyone.
However, psychological, environmental, and cultural factors are other key areas relevant
to any illness (Marks, Murray, Evans, & Estacio, 2011). The biological mechanisms of
carcinogenesis, such as inheritance of the BRCA1 or BRCA2 gene, are all part of the
social determinants framework (Healthy People 2020, 2016; Hiatt & Breen, 2008).
Social Determinants of Health Constructs
Constructs in the social determinants of health framework that I identified as risk
factors in this study were the predictor variables of age; race; and grade of cancer (I, II,
and III) in terms of health status. Age, for example, is linked to the level of social support
that MBC patients receive (Hiatt & Breen, 2008). Sources of income also are limited for
this age group because of the loss of work as the disease progresses (WHO, 2013). This
period is a significant time when MBC patients need social and family support systems.
The older that MBC patients are, the more likely it becomes that the disease will worsen.
These situations can cause anxiety and potentially increase depressive symptoms. MBC
patients need additional emotional support at this age to reduce distress.
Isolation, lack of social support, low self-esteem, body image, self-blame, and
hopelessness affect mostly younger MBC patients, whereas middle-aged patients struggle
more to cope with and deal with the diagnosis (Ostberg & Lennartson, 2007). As
mentioned previously, the effects of practical and emotional support have been studied.
According to Lyyra and Heikkinen (2006), MBC patients who lacked emotional support
were 2.5 times more likely not to have mastectomy. Ostberg and Lennartson (2007)
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reported that individuals who had more diverse sources of support had better health
outcomes.
Race plays a major role in MBC. Whites, for example, are more likely to have
more economic power than Blacks or members of other races (WHO, 2013). This
situation makes it difficult for the latter two groups to manage the outcomes of MBC. The
social determinants of health are shaped by the distribution of money, power, and
resources at the global, national, and local levels. The unequal balance of this distribution
has an impact on health disparities, the unfair and avoidable differences in health status
seen within and between countries (WHO, 2013).
Recent studies on social support and health have focused on the relationship
between social support and well-being. Individuals who are single, widowed, or divorced
have increased cancer mortality rates when compared to married or partnered individuals.
Jingzhi and Lambert (2007) studied women and men with breast cancer and found that
single men had a mortality rate of 1.96% in comparison to widowed men at 2.64% and
divorced men at 3.39%. The differences were much larger for men than for women with
breast cancer. Research has shown that social support predicts the survival rates of
patients with breast cancer (Kroenke, Kubzansky, Schernhammer, Holmes, & Kawachi,
2006).
Nature of the Study
I conducted this quantitative study using archival SEER data from 2011 to 2013.
The analysis required the same basic research principles and steps as studies using
primary data. This paper contributes to the discussion of secondary data analysis as a
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research method for MBC and psychosocial information in a study of MBC in the United
States.
Secondary Data Analysis
Johnston (2014) defined secondary analysis as “any further analysis of an existing
dataset which presents interpretations, conclusions or knowledge, either adding towards
the original investigator or a little different from those presented in the first reported
results” (p. 620). Most research begins with the desire to learn what has been studied and
what remains to be learned about a topic (Katsirikou, 2013). Secondary data analysis
takes this step further by reviewing and analyzing previously collected data on the topic
of interest (Katsirikou, 2013). Although secondary data analysis is flexible and can be
used in several ways, it also an experiential exercise with procedural and evaluative
phases, just as when collecting and evaluating primary data (Doolan & Froelicher, 2008).
Secondary data analysis remains an underused research technique in many fields,
including breast cancer.
Process of Secondary Analysis
When conducting research, the topic of interest and the RQs determine the ways
in which the researcher collects, analyzes, and interprets the data (Creswell, 2009). I
conducted this study using a quantitative research design that began with the
development of the RQs, identification of the data set, and thorough evaluation of the
data set. Ethical issues regarding this study were addressed by the original investigators,
who also ensured that all protocols had been explained and consent forms signed. The
objective of my study was to collect archival data on age; race; and grade of cancer (I, II,
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or III) from the SEER database to determine their relationship to men’s willingness to
undergo mastectomy.
Definitions of Terms
Adjuvant therapy: The use of another form of treatment such as chemotherapy or
radiation in addition to surgery (NCI, 2013).
Body image: The feelings and perceptions that individuals have about their bodies
(Brain et al., 2006).
Breast cancer: An abnormal formation of breast tissue that has grown and
infiltrated the surrounding healthy tissue of the breast (NIH, 2013).
Depression: Negative thoughts, emotions, or feelings of hopelessness that lead to
not wanting to perform normal activities (Brain et al., 2006).
In situ: The original, natural, or existing place or position (NCI, 2013).
Mastectomy: The elimination of breast tissue (NIH, 2013).
Metastatic disease: Manifestation of malignancy as a second growth arising from
the primary growth but in a new location; can be spread by lymphatic system, blood, or
bone marrow (CDC, 2013).
Perception: A personal representation of reality or experience (Larson, 2009;
WHO, 2013)
Staging: A method of classifying cancer according to the full extent of the disease
in the body. It helps in determining appropriate treatment and estimating the chances of
long-term treatment or surgery (NCI, 2013).
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Assumptions
I made the following assumptions when conducting this study:
•

The MBC secondary data in the SEER database were adequate to reach the
number needed for the study.

•

The MBC secondary data in the SEER database were valid.

•

Informed consent was signed by participants in the study conducted by the
original investigators.

•

My being a female investigator working with the NCI SEER and Behavioral
Risk Factor Surveillance System (BRFSS) registrar on a daily basis would not
affect any of the organization’s willingness to provide me with the secondary
data in a timely manner.
Scope and Delimitations

The scope of this study was limited to U.S. archival data because of the cost. The
study was limited to men 18 years of age and older because of the small target population
of men in the United States who have had breast cancer. The sample size was limited by
the scant published data in United States available for retrieval to investigate the
associative risk factors relating to MBC, namely, the psychosocial variables of age, race;
and grade of cancer (I, II, or III) to the outcome of mastectomy in the United States.
As a social change implication, the scope of the study covered only data for men
who had not yet had received a recommended yearly mammogram screening. According
to the ACS (2011), men are yet to be included in the guidelines for baseline mammogram
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for women at age 40. Because the data were archival, there was no opportunity to contact
any of the men who were in the initial study.
Limitations
One limitation of the study was that no previous researchers had specifically
focused on grading MBC. Looking for archival data took SEER personnel months to
finish. In addition, SEER personnel raised numerous objections and tried to discourage
the retrieval of the required archival data. Another limitation was the fact that the data
had been collected by other researchers, which meant no contact with the participants, no
follow-up questions, and no confirmation of the appropriateness of the original
procedures.
Significance
MBC has been diagnosed in one of every 1,000 men in the U.S. population (ACS,
2016; Fentiman et al., 2006; NCI, 2016a; NIH, 2013). The CDC (2012a) and Doornbos,
Zandee, DeGroot, and De Maagd-Rodriguez (2013) stated that many men with MBC
have yet to be diagnosed and treated. Therefore, the goal of this study was to support
positive social change in helping men to accept that they also can become the victims of
breast cancer and that they can receive the same timely treatment as women. This study
was significant for being the first study of MBC investigating the impact of the variables
of age; race; and grade of cancer (I, II, or III) on mastectomy outcome. Other researchers
have studied the stages of cancer, but not the grades of cancer.
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Implications for Social Change
Public health has many disciplines whose core principles are to improve
population health and well-being (Walden, 2014). The significance of this study is to
eliminate hindrances and the lack of information. There has been little research on the
emergence and prevention of MBC. Public knowledge might lead to more awareness and
use of mastectomy by patients at either Stage II or Stage III of MBC.
Screening and daily life changes are vital to early detection (CDC, 2012a).
Clinical professionals need to be well informed about of the reasons for not including
men in their dissemination of information about breast cancer. I hope that the results of
this study will help to eliminate the risk of MBC by educating the population. One goal
of this study was to eradicate the stereotyping of breast cancer as a female disease. The
ongoing emergence of medical technology and continued education to benefit the public
will help to ensure greater health awareness at the individual, community, and global
levels. Disparities in breast cancer mortality among men are apparent. Results will add to
the current knowledge base by informing the public, clinical professionals, and patients
about the relationship between the predictors of age; race; and grade of cancer (I, II, or
III) on the outcome of mastectomy in MBC.
Summary
Chapter 1 introduced the problem, nature of the study, significance of the study,
and the RQs. Also included was information about the assumptions, scope and
delimitations, and the limitations of the study. In Chapter 2, I present the literature
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review, rationale for conducting the study, theoretical foundation, and conceptual
framework.
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Chapter 2: Literature Review
Introduction
MBC occurs infrequently, and there has been a gap in knowledge about the
disease because of limited research and inadequate funding inside and outside of the
United States (Chavez-MacGregor et al., 2013; Kornegoor et al., 2012). The incidence of
MBC is increasing globally. The purpose of this study was to understand the influence of
the predictors of age; race; and grade of cancer (I, II, or III) on the outcome of
mastectomy in MBC.
Literature Review Strategy
I searched the Medline and ProQuest databases to obtain relevant literature on the
topic of MBC. The key search terms under the medical subject heading MeSh were
breast in men; cancer; Grades I, II & III; male; social support; altered body image;
coping with breast cancer; depressive symptoms; breast cancer; and family support. The
search for relevant literature spanned 2001 to 2014, but the archival data used in the study
were from 2011 to 2013.
Rationale for the Study
The purpose of this study was to understand the influence of the predictors of age;
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. This
quantitative investigation focused on archival data from 2011 to 2013 obtained from the
SEER database. The data were for men 18 years of age and older who had been
diagnosed with breast cancer and who considered mastectomy as part of treatment. Only
a few studies have sought to identify the influence of the variables of age, race, and grade
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of cancer in relation to mastectomy in men, making this study even more important in
filling the gap in the research.
Social Predictors of MBC
Age; race; and grade of cancer (I, II and III) were the IVs determining
mastectomy for patients with MBC. Brain et al. (2006) reported a prevalence of
psychosocial variables in 161 men using a cross-sectional questionnaire to determine
whether age of diagnosis resulted in mastectomy. The questionnaire contained the
variables of anxiety, depressive symptoms, cancer-specific distress, body image, and
coping and support needs, as well as demographic variables (Brain et al., 2006). Results
indicated that anxiety was not reported because depressive symptoms associated with
altered body image was at 35% of the variance (p < .001). The clinical level of the
anxiety reported was 6%, while 23% of those reported a rise in cancer-specific distress
(Brain et al., 2006). Body image, avoidance of coping, and emotional support was at 51%
(p < .001; Brain et al., 2006). Brain et al. stated that the largest impediment to
accommodating the disease was the inability to cope with the disease, the altered body
image, and the lack of support needs. Brain et al. concluded that age affected MBC
patients in terms of their body image and psychological needs.
Merletti, Galassi, and Spadea (2009) asserted that timely access to health care is
essential to diagnose and treat breast cancer, and reduce the mortality and morbidity
rates, adding to the gap identified in Chapter 1 (Burson et al., 2009; Munn, 2001; Rachid
et al., 2009). Breast cancer is 100 times more prevalent in women than in men, and even
though most cases of MBC are diagnosed in men between the ages of 60 and 70 years,
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men of any age can become MBC patients (Rachid et al., 2009). Several researchers (e.g.,
Brain et al., 2006; Burson et al., 2009; Hiatt & Breen, 2008; Robinson et al., 2008;
Rosenbaum et al., 2004) have stated that among unmarried men, anxiety, depressive
symptoms, altered body image, and the lack of coping mechanisms and emotional
support have an impact on their self-esteem, with altered body image having the greatest
impact. Among married men, distress has been related to decreased satisfaction in terms
of intimacy in the relationship, lowered sexual function, and less appreciation of spouse
or partner (Brain et al., 2006). Additional problems encountered among older men
include decreased physiological arousal, decreased sexual arousal, decreased interest in
sexual attractiveness, and no hope of achieving orgasm (Brain et al., 2006).
MBC accounts for only 1% of all breast cancers (NCI, 2016a). Researchers have
reported on the evaluation, treatment, and results of male patients with MBC (Ahmed et
al., 2012; Gómez-Raposo, Tévar, Moyano, López Gómez, & Casado, 2010). Male
patients with a histological diagnosis of breast cancer from 2001 to 2010 who had been
evaluated previously (Ahmed et al., 2012; Fentiman et al., 2006; NCI, 2013; NIH, 2013)
have been given the recommendation to undergo modified radical mastectomy as a
treatment option.
A diagnosis of DCIS among men is rare because of the lack of screening detection
methods, so MBC usually presents as a profound mass (Doyle et al., 2011 Fentiman et
al., 2006; NCI, 2013; NIH, 2013). Typically, MBC presents with a unilateral, painless,
subareolar mass that often is located away from the nipple (Doyle et al., 2011; Fentiman
et al., 2006; NCI, 2013; NIH, 2013). Twenty-nine percent of MBC patients with invasive
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ductal cancer have surgery; 17% have surgery for tumors, particularly unadulterated
DCIS (Vetto, 2010).
Researchers have found that MBC cases are much more common in relatives with
the BRCA2 gene than in those with the BRCA1 gene (Fentiman et al., 2006; Mathew et
al., 2008; NCI, 2013; NIH, 2013). Fentiman et al. (2006) studied 54 participants with
MBC who lacked BRCA1 mutations, but a BRCA2 transfiguration was found in two
participants. The same researchers confirmed that five patients had BRCA2 mutations
inherited from first-degree relatives with breast cancer.
Work-related risks associated with a diagnosis of MBC include environments
with elevated temperatures and exhaust fumes; however, electromagnetic fields have not
yet been implicated (Gómez-Raposo et al., 2010). Patients who have experienced
hyperestrogenization resulting from Klinefelter’s, gonadal dysfunction, obesity, and high
alcohol consumption, along with exposure to radiation, have an increased risk of
developing MBC (Fentiman et al., 2006; Gómez-Raposo et al., 2010). Nipple inversion
usually presents when a lump is discovered, but in 40% of men, this discovery often does
not come until Stage III or Stage IV of the disease. Most MBC tumors are ductal; 10%
are DCIS. Surgery performed on patients with this condition usually involves
mastectomy with axillary clearance or sentinel node biopsy. The decision to undergo
radiotherapy is indicated by the stage of MBC and is similar to female breast cancer
(Fentiman et al., 2006; Gómez-Raposo et al., 2010). Hormone therapy is the core
treatment for metastatic disease, according to Fentiman et al. (2006), but
chemotherapeutic agents also can be used to provide palliation. There is a need for
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national initiatives to improve information about and support for treatment of MBC. This
study will aid in filling the gap.
Theoretical Foundation
Much research has been conducted on cancer in general, but the majority of
studies have focused primarily on female breast cancer and have excluded MBC. The
purpose of this study was to understand the influence of the predictors of age; race; and
grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. The social
determinants of health play an essential role in enhancing the psychological well-being of
these patients in terms of social support.
Ruddy and Winer (2013) stated that more research is needed to explore the
relationship between coping strategies and emotions experienced by individuals dealing
with MBC. Brain et al. (2006) stressed that further study will help to capture information
relevant to the pattern of anxiety, depressive symptoms, distress, body image issues,
coping mechanisms, and emotional support from initial diagnosis through various
treatment regimens.
Conceptual Framework
The study was guided by the social determinants of health framework, which was
designed to aid in conceptualizing how social determinants and sociological factors
interact with other factors in the etiology of MBC and to realize changes over time. The
framework begins with the cancer series, added levels of analysis, and considered the
impact of interventions in the management of MBC (Hiatt & Breen, 2008). As mentioned
in Chapter 1, the social determinants of health are the conditions relevant to how people
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grow, live, work, and age. These conditions are impacted by the distribution of money,
power, and resources at the global, national, and local levels. Following are details about
the constructs in the social determinants of health framework.
Social Support
Social support, one construct in the social determinants of health framework and
the main construct of this study, was defined by Rab (2012) as “availability of support
which refers to the degree to which interpersonal relationships serve a particular
function” (p. 2). Social support is an important predictor in the ability of individuals to
cope with difficult circumstance and adjust to psychological and social demands. Several
studies, according to Rab, have indicated that men’s perceptions of close supportive
relationships with their spouses and close friends are positively correlated with their
ability to cope with MBC.
Age
Age is a sociological predicator variable. As a construct in the social determinants
of health framework, age determines how well MBC patients handle anxiety in terms of
worry and fear whenever the symptoms become more severe or when undergoing testing
to determine whether the cancer has progressed (Rab, 2012). Some of the most common
fears are painful procedures associated with the disease and side effects such as hair loss,
nausea, fatigue, and pain (Rab, 2012). MBC patients worry about disruptions to their
daily lives that can lead to fear and anxiety because of their inability to work. Older MBC
patients who have already reached retirement worry less.
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The factors predicting anxiety include personal history of depression, personal
history of anxiety, painful treatment protocols, and difficulty controlling bladder during
therapy (Brain et al., 2006, Rab, 2012). This last factor is of particular relevance to men
age 65 years and older. During remission, MBC patients are required to have follow-up
visits with their oncologists to manage MBC. Anxiety and worry intensify at this stage
because of the fear of negative updates.
Race
Race is another construct in the social determinants of health framework. Racial
disparities exist in the management of MBC in terms early diagnosis and access to health
care. Whites, more so than Blacks, are mostly insured (WHO, 2013). Blacks are
underinsured because of the lack of social support, poor employment prospects, and lack
of resources. Having insufficient resources can cause distress that manifests as
depression, anxiety, insomnia, anorexia, poor concentration, and the inability to function
in daily chores.
Cancer Grade I
Adding to the social determinants of health framework, the grade of cancer refers
to the aggressiveness of its management. Grade I is a low grade; in Grade II, cells
become differentiated and require treatment; and in Grade III, the cells grow and spread
rapidly (NCI, 2013). MBC patients at this latter stage have an inability to cope, and they
can experience frustration and emotional distress. Grade I denial in breast cancer leads to
deregulation of the immune system and results in long-term physical and emotional
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problems that cause distress. Many patients with Grade 1 cancer who are waiting for
MBC test results experience tremendous distress.
Cancer Grade II
Grade II is another construct of the social determinants of health framework.
MBC patients who seek a mastectomy during Grade II should report body image issues to
their partners or caregivers to seek emotional help in order to deal with the disease (Rab,
2012). Caregivers or partners might offer advice regarding the treatment to follow in
terms of breast-conserving surgery, or reconstructive surgery, to enhance body image
(Rab, 2012).
Cancer Grade III
Grade III is another construct in the social determinants of health framework.
Patients with this grade of cancer need help coping with the effects of chemotherapy on
MBC (NCI, 2013). MBC patients report very poor physical and emotional qualities of
life when coping with the treatment regimen. The side effects of antiestrogen during
treatment can lead to weight gain, fatigue, and depression (Rudy & Winer, 2013).
Because of the side effects of treatment at any stage of cancer, men with MBC need
emotional support (Brain et al., 2006).
Psychosocial comorbidities also can have a negative effect on MBC patients’
emotions (Brain et al., 2006). Feelings of uncertainty give rise to feelings of
hopelessness. The absence of social networks can lead to decreased survival rates and
rapidly increase the course of the disease.
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Supportive Care
Nursing staff, paramedics, ancillary staff, and social support staff have a role in
alleviating the symptoms and managing the welfare of MBC patients in terms of
chemotherapy and pain management. This role can result in a positive relationship with
MBC patients. The social determinants of health framework offered a sound theoretical
foundation for this study. The purpose of this study was to understand the influence of the
predictors of age; race; and grade of cancer (I, II, or III) on the outcome of mastectomy in
MBC.
Epidemiology
The yearly report incidence of MBC in Europe is one in 100,000, and less than
1% of all breast cancer patients are men, statistics that are similar to those in the United
States (Fentiman et al., 2006). According to Weiss, Moysich, and Swede (2005), the
epidemiology of MBC resembles that of female breast cancer. Major genetic factors
connected with an increased risk of breast cancer for men include BRCA2 mutations,
which are believed to account for most cases of inherited breast cancer (Weiss et al.,
2005). Klinefelter’s syndrome is another risk factor, as is a positive family BRCA I or II
history (Weiss et al., 2005). Alleged genetic factors include AR gene mutations, CYP17
polymorphism, Cowden syndrome, and CHEK2 (Weiss et al., 2005).
Epidemiologic risk factors for MBC include disorders relating to hormonal
imbalances such as obesity and testicular disorders (e.g., cryptorchidism, mumps orchitis,
and orchiectomy), as well radiation exposure (Peschos, 2008). Other epidemiologic risk
factors include prostate cancer as a secondary causation, prostate cancer treatment,
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gynecomastia, and occupational exposure (Peschos, 2008), such as working in areas that
contain polycyclic aromatic hydrocarbons, electromagnetic fields, or high temperatures.
Another factor is dietary intake. Suggested examples could be “meat intake, fruit, and
vegetable consumption, and alcohol intake” (Weiss et al., 2005, p. 2).
Race
Race accounts for the increased risk of developing a type of cancer that is
genetically inclined or inherited. For example, the triple negative breast cancer gene was
seen mostly in men of Black ancestry having receptors for estrogen and progesterone.
This Black ancestry origin inhibits the response to medications that block estrogen
production, making chemotherapy the treatment of choice for this group of men (ACS,
2011). Ashkenazi Jewish men have a higher risk than men from other ethnic groups of
carrying the BRCA gene. According to Chavez-MacGregor et al. (2013), White men
have of the highest incidence of breast cancer, followed by Blacks and Hispanic
Americans. They also found that Black men are more likely to die from MBC because of
the advanced stage of the disease at diagnosis.
Pavinato (2008) conducted a retrospective study of 146 men who were diagnosed
with MBC between 1990 and 2007. Results showed that by the time the men found out
that they had breast cancer, it was already at a later stage and had spread to the lymph
nodes and then had metastasized to other organs. Reynolds (2007) analyzed race and
other “predictors of treatment and survival among 510 men over 65 yrs. diagnosed with
stage I-III breast cancer between 1991 and 2002” (p. 1), noting that in regard to 5-year
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survival rates, approximately 456 (90%) of survivors were White men, and 34 (6.6%)
were Black men.
Ethnic Factors
Sandhu et al. (2012) stated that African and Ashkenazi Jewish heritages have
been associated with an increased risk of MBC. Sandhu et al. remarked that MBC
accounted for between 7% and 14% of all breast cancers in sub-Saharan Africa at the
time of the study. Black men have the highest occurrence in the United States (Sandhu et
al., 2012). Specific factors responsible for the increased incidence in these ethnic groups
are not known. The increased risk in Ashkenazi Jewish populations is the result of a high
prevalence of BRCA mutations, also known as founder mutations, that are specific to that
population (Sandhu et al., 2012). Ethnicity was not a factor in my study because of the
limited number of men diagnosed with MBC.
Age
MBC is usually diagnosed at an older age than cancer is diagnosed in women.
Men who are diagnosed often are not treated because of the advanced spread of the
disease. The standard age for men at diagnosis is > 65 years (Chavez-MacGregor et al.,
2013). However, the current study was limited to men 18 years of age and older. Table 1
shows the age-adjusted SEER incidence rates by year and race for MBC (NCI, 2014) in
nine areas of the country (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New
Mexico, Seattle, Utah, and Atlanta). Rates were per 100,000 and were age-adjusted based
on the 2000 standard population in the United States.
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Table 1
Age-Adjusted SEER Incidence Rates by Year and Race
Year of diagnosis
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012

Other

White
1.16
1.22
1.15
1.33
1.21
1.06
1.16
1.11
1.18
1.19
1.24
1.42
1.35

Black
1.14
1.22
1.13
1.34
1.23
1.15
1.19
1.14
1.2
1.25
1.13
1.37
1.34

2.86
1.66
1.95
1.85
1.61
0
1.54
1.82
1.43
0
2.93
2.74
2.1

Gender
Although breast cancer cases are usually diagnosed in women, men make up 1%
of breast cancer cases (ACS, 2011). In fact, the rates for women and men as well as
different ethnicity groups and age groups in the United States vary. However, because my
study focused on men only, so gender was not an issue.
Mortality Rate in United States
An estimated new cases of female breast cancer in the United States are 249,260
reported in 2016 and only 2,600 new cases of MBC (NCI, 2016a). In the United States,
440 men were estimated to die from the disease. Table 2 shows invasive MBC incidence
rates in six major regions of the United States, with the highest incidence from 2008 to
2012.
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Table 2
Invasive MBC Incidence Rates in Six Major U.S. States 2008-2012
Region

Population at risk

cases

Crude rate

Age-adjusted rate

95% CI

Pennsylvania

30,951,263

567

1.83

1.64

[1.50, 1.78]

Florida

46,172,326

885

1.92

1.58

[1.48, 1.69]

New York

46,968,042

707

1.51

1.50

[1.39, 1.62]

Illinois

31,450,263

400

1.27

1.34

[1.21, 1.48]

California

92,764,862

953

1.03

1.16

[1.08, 1.24]

Texas

62,557,960

568

0.91

1.10

[1.01, 1.20]

310,864,716

4,080

1.31

1.35

[1.31, 1.39]

Combined

Global Rates of MBC
In England, 300 men and 41,000 women are diagnosed with breast cancer
annually (NCI, 2014). Even though most of prevention campaigns are aimed at women
rather than men, research carried out at Texas University indicated that MBC cases are
rising and that most of the men are detecting it at a very late stage. The study stated that
male cases increased from 0.86 to 1.08 per 100,000 men in 20 years (“Male Breast
Cancer Numbers Rising Most Fail to Spot It Until It Has Spread to Lymph Nodes,”
2004). The percentage globally is higher, with breast cancer being diagnosed in Zambia
at a rate of 15% and 6% in Egypt and Tanzania (“Male Breast Cancer Numbers Rising
Most Fail to Spot It Until It Has Spread to Lymph Nodes,” 2004).
Grading
Grade of MBC is a rating that tells physicians how the cancer is behaving
microscopically. Looking into a microscope, one can see that MBC cells are
differentiated into an alarming appearance and pattern that is unlike normal cells. There
also are other ways of determining the grade of MBC. Two grading and scoring systems
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are the Nottingham Histologic Score System and the Elston-Ellis Modification of ScarffBloom-Richardson Grading System. Using these systems, pathologists take into account
three factors: (a) gland formation number, or differentiation, meaning how well it will
replicate a normal cell; (b) pleomorphism, or nuclear features, meaning how bad the cell
looks under a microscope; and (c) mitotic pattern or division activity, meaning creating
family.
Histologic Grade and Score
To determine glandular (acinar)/tubular differentiation, the following rating
system is used:
Score 1: indicates tumor > 75% forming glandular/tubular structures.
Score 2: indicates tumor is 10% to 75% forming glandular/tubular structures
Score 3: indicates when tumor is < 10% and is forming glandular/tubular
structures.
To grade nuclear pleomorphism of MBC, the following scoring system is used:
Score 1: Small nuclei with a slightly increase in size in comparison to normal
male breast epithelial cells will be visible under a microscope, Uniform nuclear
chromatin appears regular and uniform, and has slight variations in size.
Score 2: Under a microscope, these cells appear usually larger than normal cells,
with nucleoli medium in size and shape.
Score 3: During this stage, the cells exhibit remarkable enlarged size with
prominent nucleoli, and they look so bizarre in shape.
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Mitotic Characteristics of MBC Grade
This technique requires use of a high-definition microscope. BC cells are
manually counted on a slide to see the mitotic ability on a 10X high power fields using a
high power field 0.55 mm condenser. Following is the scoring system:
Score 1: ≤ 7 mitoses MBC cells per 10X high-power fields.
Score 2: 8 to 14 mitoses MBC cells per 10X high-power fields.
Score 3: ≥ 15 mitoses MBC cells per 10X high-power fields. Once the pathologist
looks at all of the cells, then an overall grade is determined as Grade 1, Grade II, or
Grade III cancer. Grade 1 tumors have a score of 3 to 5, Grade 2 tumors have a score of 6
or 7, and Grade 3 tumors have a score of 8 or 9.
Staging
The NCI (2014) accepted the following tests to define the extent of cancer in the
body:
•

Radionuclide: This is a radioactive substance that uses a blue dye injected
near the tumor that flows through the lymph ducts to the nodes. The first
lymph node to receive the dye is extracted and viewed under the microscope
for cancer cells (Macmillan Cancer Support, 2013; NCI, 2014).

•

CT scan (CAT scan): This is a scan that contains dye contrast that takes a
series of pictures of the affected area inside the body from different views
(Macmillan Cancer Support, 2013; NCI, 2014).

•

Bone scan: A bone scan usually is done to check for rapidly dividing cancer
cells. It is performed by injecting a radioactive material into the vein that
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travels through the bloodstream to lodge in the bone. It is detected by the
scanner (Macmillan Cancer Support, 2013; NCI, 2014).
•

Positron Emission Tomography Scan (PET): This scan is used to find
malignant or tumor cells in the body. It is done by injecting a radioactive
glucose sugar into the vein; the PET scanner rotates around the body, taking
pictures of cells aided by illumination of glucose that helps the cancer cells to
appear brighter on the cancer cells, which occurs because cancer cells take up
more glucose than normal cells do. (NCI, 2014)

The medium allows oncologists to detect the stage of breast cancer in order to
describe the size of the tumor and determine whether it has spread to other organs
(Macmillan Cancer Support, 2013; NCI, 2014). The initial step in assessing a suspicious
breast lump in a man is to perform a mammogram (Fentiman et al., 2006; Giordano,
2005). The sensitivity and specificity rates of a mammogram to diagnose MBC are about
92% and 90%, respectively (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al.,
2010). Usually, a mammogram can differentiate between a malignancy and
gynecomastia. The radiological features indicative of malignancy include, but are not
limited to, proximity away from the nipple, spiculated margins, and microcalcifications
that are less common in men than in women who have breast cancer (Fentiman et al.,
2006; Giordano, 2005; Gómez-Raposo et al., 2010).
Risk Factors
Gómez-Raposo et al. (2010) conducted a prospective study using NIH-AARP
Diet, a health study of 324,920 men, of which 121 developed breast cancer. A notable
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risk was seen in the men who had first-degree relatives with breast cancer (RR 1.92), a
history of bone fracture after age 45 (RR 2.2), obesity (RR.1.79), and decreased levels of
physical activity (Gómez-Raposo et al., 2010). Most of the men in the study had no
identifiable risk factors; however, several risk factors had been identified in their study,
including genetics (BRCA1, BRCA2 mutations); Klinefelter’s syndrome, ethnic factors,
family history of breast cancer, and Ashkenazi Jewish heritage. Endocrine risks included
estrogen excess, which has to do with liver disease; exogenous estrogens; lifestyle; and
environmental and occupational exposure (Gómez-Raposo et al., 2010).
Klinefelter’s syndrome is the worst threat for emergent MBC that occurs in
approximately one in 1,000 men (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo
et al., 2010). “Klinefelter’s syndrome is characterized by the addition of at least one X
chromosome to the normal XY karyotype which is usually 47XXY” (Gómez-Raposo et
al., 2010, p. 451). It is characterized by enlarged testes, gynecomastia, high serum
gonadotropins, and low serum testosterone levels (Fentiman et al., 2006; Giordano, 2005;
Gómez-Raposo et al., 2010).
Ruddy and Winer (2013) conducted a systematic review of literature relevant to
MBC risk factors, biological characteristics, presentation, prognosis, treatment, and
survivorship between 1987 and 2012 and included 20 patients. Results showed that a
BRCA2 mutation, age, conditions, estrogen/androgen ratio, and radiation were proven
risk factors. Ruddy and Winer concluded that even though the disease biology is very
distinct in men, the diagnostic approaches and treatment protocols for men are generally
extrapolated from those used with women who have cancer. Reasons include inadequate
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research with male participants and that survivorship might include sexual and hormonal
side effects of endocrine therapies as well as the psychosocial impact of breast cancer.
The risk of breast cancer in genetically affected individuals is 20 to 50 times
higher than in 46XY men (Gómez-Raposo et al., 2010). The risk increases with inherited
BRCA2 rather than BRCA1 mutations (Fentiman et al., 2006; Giordano, 2005; GómezRaposo et al., 2010). An example would be the genetically susceptible mother in a family
who has been diagnosed with breast cancer. If she had given birth to only male children,
then the chances of one of them inheriting the BRCA2 gene would be great (GómezRaposo et al., 2010). Testicular conditions are another risk factor associated with MBC.
They include enlarged or undescended testes, congenital inguinal hernia, orchiectomy,
orchitis, and infertility (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al.,
2010).
Diagnosis
MBC usually presents as a palpable mass with a unilateral, painless subareolar
mass that often is located away from the nipple (Doyle et al., 2011; Fentiman et al., 2006;
NIH, 2013). MBC is different from gynecomastia, which often is painful, and although
frequently asymmetrical or unilateral, it is subareolar and central in position (Doyle et al.,
2011; Fentiman et al., 2006; NIH, 2013). Ultrasound can be an effective diagnostic tool
to identify possible node attachment in male patients. MBC on an ultrasound image can
be invasive and can typically appear as a solid lesion that requires a biopsy (Fentiman et
al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010) to confirm the diagnosis.
Estrogen receptor, progesterone receptor, and Her2-neu status should be assessed in male
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patients (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). A core
biopsy is chosen for later stages of cancer so that a definitive diagnosis can be made
(Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010).
The diagnostic assessment and staging systems for MBC patients are the same as
for women with breast cancer (Fentiman et al., 2006; Giordano, 2005). The scope of the
cancer is recognized by laboratory tests, radiography, and bone and CT scans (Fentiman
et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). The tumor stage is determined
using the American Joint Committee on Cancer’s classification system, which considers
tumor size, nodal involvement, and distant metastases (as cited in Gómez-Raposo et al.,
2010). Only 48% of MBC cases are diagnosed at Stage I or Stage II; most men tend to be
diagnosed at later stages of the disease (Fentiman et al., 2006; Giordano, 2005; GómezRaposo et al., 2010).
Prognosis
The most significant prognostic pointers are stage of cancer at diagnosis and
position of the lymph node (Fentiman et al., 2006). The normal estimated survivor rate
for MBC in comparison to other breast cancers is about 40% to 65%, with a 5-year
average, but when clustered by appearance in MBC, the 5-year survival rate is 75% to
100% for a Grade I diagnosis. The percentage decreases to 50% to 80% for a Grade II
diagnosis and then declines even further to 30% to 60% for a Grade III diagnosis (Fazel
& Pitsinis, 2013; Fentiman et al., 2006).
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Grading
Grade of MBC is a rating that tells physicians how the cancer is behaving
microscopically. Looking into a microscope, one can see that MBC cells are
differentiated into an alarming appearance and pattern unlike normal cells. A laboratory
scientist with oncology experience rates the cancer on a scale ranging from 1 to 3
pending pathology confirmation. When the grade is at the tumor level, the cells look
different from normal cells. A low-grade breast cancer grows at a slower rate than a
Grade II or a Grade III cancer, both of which are high-dividing cells that are likely to
spread rapidly and are indicative of a poor prognosis and a poor survival rate because of
their resistance to chemotherapy and radiation (NCI, 2012).
MBC Grade and Treatments
MBC treatment oncologists take into account the tumor grade and other critical
factors such as the stage of MBC, age of the patient with MBC, and the patient’s overall
health. This is the first step in determining the most appropriate regimen for the MBC
client after grading and staging (NCI, 2012).
Treatment of Early Stage I and Stage II Breast Cancer
Management of localized, invasive early MBC follows the same general treatment
protocols as for female breast cancer (Fentiman et al., 2006; Giordano, 2005; GómezRaposo et al., 2010). The treatments, according to Omene and Tiersten (2010), are
customary modified radical mastectomy with axillary lymph node dissection, as well as
lymph node biopsy. Breast-conserving therapy is not an option for men with early Stage I
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and Stage II MBC because men lack breast tissue; however, it remains an option for
women (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010).
Another treatment for early Stage I and Stage II of MBC is adjuvant radiotherapy.
Men tend to be treated less often than women for postmastectomy radiation because they
usually have more nipple or skin involvement. The deciding factor in selecting adjuvant
therapy is when men have positive lymph nodes or tumors larger than 2 inches (GómezRaposo et al., 2010).
An additional treatment for early Stage I and Stage II of MBC is adjuvant
hormonal therapy. Tamoxifen in MBC is frequently used because of the reduced risk
associated with reappearance and death. Adjuvant tamoxifen is traditionally used in
patients with Stage II and Stage III cancer (Gómez-Raposo et al., 2010). Adjuvant
chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil also is widely
used in MBC. These choices are based on performance benefits from the perspective of
clinical trials; a 5-year survival rate has been noted in some studies at > 80% significance
(Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). It is recommended
for men with an intermediate or a high risk of primary breast cancer (Fentiman et al.,
2006; Giordano, 2005; Gómez-Raposo et al., 2010).
Treatment of Stage III or Stage IV Cancer
Men who have Stage III or Stage IV breast cancer (Gómez-Raposo et al., 2010;
Leong, 2005) undergo treatment that is similar to that for women. Chemotherapy is
usually started initially, and surgery might be an option if tumors can be removed
surgically (Fentiman et al., 2006; Giordano, 2005). Patients usually are given radiation
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therapy and adjuvant tamoxifen for HR-positive disease after mastectomy (Fentiman et
al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). Induction hormone therapy
represents an interesting option for most patients and is preferred to chemotherapy
(Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010; Sousa, Moser, &
Cardoso, 2013). Gómez-Raposo et al. (2010) reported that 24 male participants in their
study who had Stage II breast cancer were treated at the NCI with adjuvant
cyclophosphamide, methotrexate, and fluorouracil.
Surgery
Fields, Devitt, Fisher, and Rabinovitch (2013) sought to determine the stagespecific management of MBC using either surgery or radiation. A total of 4,276 cases of
MBC were obtained from the SEER database in their study. Results indicated that 87.4%
used mastectomy and 12.6% used breast-conserving surgery (Fields et al., 2013). Fields
et al. concluded that the outcomes for MBC improve with therapy use in unscreened
populations.
Jablon (2014) conducted a study with a sample of 1,951 men who had localized
breast cancer and found that 70% of the participants had had a lumpectomy with
radiation. Results highlighted the need for men to be offered mastectomy instead of
lumpectomy. The justification for this procedure is that men often have central tumors
around the nipple area, meaning that surgery can be performed without sacrificing the
nipple. Nipple reconstruction also might be done surgically, and some patients would
rather tattoo in order to restore body image (Fentiman et al., 2006).
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Deciding on the treatment to follow is customized to the stage at presentation. A
sentinel lymph node biopsy is an option for patients with MBC, but limited data have
been available to prove the effectiveness of this option (Fentiman et al., 2006; Giordano,
2005; Gómez-Raposo et al., 2010). Most research has found support for adjuvant
hormonal therapy, radiotherapy, and chemotherapy for MBC, as is the case for women
with breast cancer (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010).
Tamoxifen is one of the most recommended adjuvant hormonal therapies, even though
data relevant to MBC patients have been scant (Fentiman et al., 2006; Giordano, 2005;
Gómez-Raposo et al., 2010). More research is needed to better understand MBC and
improve its management and prognosis (Constantinou & Fentiman, 2012; Gómez-Raposo
et al., 2010).
Literature Review Related to Key Variables and/or Concepts
Social networking is a strong medium of communication that reaches
communities, provides social and family support, and is linked to the framework of the
research. The constructs of the social determinants of health framework include
psychosocial predictor variables such as anxiety, depressive symptoms, distress, body
image, coping mechanism, and emotional support. These predictors can encourage
healthy choices and lifestyles, both of which have a strong influence on health and the
ways in which people cope with demanding life issues and circumstances. Social support
includes practical assistance; financial help; and the availability of information, advice,
and psychological support.
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Anxiety, a construct in the social determinants of health framework. is tied to the
emotional support available to MBC patients. Lack of economic resources, such as loss
of work as the disease progresses, will mean a reduction in income. This is a significant
time when MBC patients need social and family support. Anxiety can lead to a potential
increase in depressive symptoms, the second construct in the framework. MBC patients
need additional emotional support during this phase of the disease to reduce distress, the
third construct. Isolation; lack of social support; low self-esteem, which is part of body
image; self-blame; and hopelessness can affect their ability to cope with a diagnosis of
MBC.
The effects of practical and emotional support have been studied. According to
Lyyra and Heikkinen (2006), MBC patients lacking emotional support were 2.5 times
higher than those who had emotional support in terms of the decision to have a
mastectomy. Ostberg and Lennartson (2007) reported that individuals with diverse
sources of support have better health outcomes.
In conclusion, the social determinants of health framework was a sound
foundation for this study. The framework supported and reinforced the basic constructs of
this study, which was centered on the social support construct of the framework. The
purpose of this study was to understand the influence of the predictors of age; race; and
grade of cancer (I, II, or III) on the outcome of mastectomy in MBC.
Summary and Conclusions
Chapter 2 summarized the major literature related to the predictors of mastectomy
in Grade II or Grade III of MBC; diagnosis; staging; and treatment options. I reviewed

46
the variables and discussed the social determinants of health framework as it was used in
the current study. This research will fill gaps in the literature relevant to the topic of
MBC. In Chapter 3, I describe the methodology, my role as the researcher, instrument
used, informed consents, sample and target population, and the recruitment and approval
processes necessary to conduct the research.
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Chapter 3: Research Method
Introduction
The purpose of this study was to understand the influence of the predictors of age;
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. This
chapter explains the study design, sample, and procedures. Although the analysis of
secondary analysis data is flexible and can be used in several ways, it also is an empirical
exercise and an efficient method with procedural and evaluative stages, just as in
collecting and evaluating primary data (Katsirikou, 2013). This study confirmed that
secondary data analysis is a viable process of inquiry when a systematic procedure is
followed and presents an illustrative research application using a quantitative analysis
(Katsirikou, 2013). I used this medium to test the RQs and provide an explanation of the
answers to the RQs using what Creswell (2009) described as a quantitative research
design. “Quantitative analysis should contain the quantifiable variable by observation
performed retrospectively, which varies on institution or organization” (Creswell, 2009,
p. 50). I followed a quantitative research design to compute the contributory relationship
obtained during the MBC survey with the numeric data through a secondary data
approach (Creswell, 2009).
Study Design and Rationale
The purpose of this cross-sectional survey was to generalize the results from the
target population of MBC patients so that inferences can be made about the influence of
age; race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC.
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Research Design and Approach
This quantitative study followed a retrospective design. Secondary data collected
between 2011 and 2013 were retrieved from the SEER database of the NCI. Secondary
data were suitable for use in this study based on the limited data available across the
United States and Europe on BRFSS and quality of life on survivorship data. I conducted
this retrospective study to review the differences in MBC stage at diagnosis, demographic
data, tumor size, and sociological variables from 2011 to 2013 previously surveyed in
order to address the RQs. The purpose of this study was to understand the influence of
the predictors of age; race; and grade of cancer (I, II, or III) on the outcome of
mastectomy in MBC. The results highlighted the issue of health care availability, health
care practices, and the need for education and information about MBC.
Research Questions and Hypotheses
RQ1: How will age impact knowledge related to mastectomy in MBC?
H01: Age will not relate to mastectomy in MBC.
Ha1: Age will relate to mastectomy in MBC.
RQ2: How will race account for MBC in relation to mastectomy?
H02: Race does not account for MBC in relation to mastectomy.
Ha2: Race does account for MBC in relation to mastectomy.
RQ3: Is there a predictive relationship between mastectomy and Grade I, II, or III
cancer in MBC?
H03: There is no predictive relationship between mastectomy and Grade I, II, or
III cancer in MBC.
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Ha3: There is predictive relationship with mastectomy and Grade I, II, or III
cancer in MBC.
All RQs were analyzed using logistic regression. Modeling included all risk
factors mentioned earlier, in addition to all demographic variables. I also included data
from more than 427 patients after inclusion of my variables; data from the SEER
database on other cancer stages were excluded.
The sample size calculation formula was as follows:
Z2 * (p) * (1-p)
ss =
c2

Where:
Z = Z value (e.g. 1.96 to 95% confidence level)
p = percentage picking a choice, expressed as decimal
(.5 used for sample size needed) due to the number of mastectomies was hoped to be at
50% of MBC
c = confidence interval (CI), expressed as decimal (e.g., .04 = ±4)
Sample size 427; 95% confidence using a U.S. standard population of 100,000, at a 50%
MBC the CI (4.73), at 99% sample size 427 confidence using the same 100,000 pop at
50% MBC the CI (6.23; Capasso et al., 2013).
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Prevalence=

persons with a given health indicator during a specified time period
X 100
population during the same time period

Prevalence=

125
100,000 X 100 = 0.12%

Per 100,000 standard population
Methodology
Knowing that there were inadequate resources regarding time, money, and the
number of MBC cases available prompted the use of a retrospective cohort study as a
suitable design. The IVs in this study were age; race; and grade (I, II, or III) of cancer;
the DV was outcome of mastectomy. The purpose of this study was to understand the
influence of the IVs on the DV.
Setting and Sample
Data on male patients of all racial and ethnic groups reported from the 17
registries that provide information to the SEER database who had been diagnosed with
breast cancer between 2011 and 2013 served as the target population. The sample
comprised data on men diagnosed with breast cancer based on the following criteria:
(a) 18 years of age and older, (b) residing in the United States, (c) year of diagnosis: 2011
to 2013 inclusive; (d) tumor size, (e) race/ethnicity: all races/ethnicities reported;
(f) grade of cancer at diagnosis; and (g) mastectomy. Stratification of Grades II and III
from the secondary data commenced once approval was received and the confidentiality
agreement was signed.
Informed Consent
I assumed that informed consent had been given by the men whose data were
reported to the SEER database to the original investigators. Using archival data meant
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that I did not have to obtain any further consent from any of the original participants and
that I could conduct a secondary analysis freely (Grinyer, 2009).
The 17 registries obtained information about the participants’ ages; race; and
grade of cancer (I, II, or II), along with mastectomy status, by using an interview
protocol. I assumed that they had conducted these interviews following confidentiality
and HIPPA compliance protocols. All documents related to the study are stored in a
secured and fireproof cabinet under key and lock. They will remain there for 5 years after
publication of the data, after which time all data will be shredded or electronically
destroyed.
Instrumentation and Materials
I obtained archival data from the NCI’s SEER database. SEER, since its inception
in 1973, has collected information on cancer incidence and survival rates from 17
population-based registries in geographic areas that make up 26% of the U.S. population
(Klein et al., 2011; SEER, n.d.a). The SEER registry database is a wide-ranging source of
U.S. population-based information and includes data on stage of cancer at diagnosis and
patient survival rates. SEER collects and stores demographic data on patients, primary
tumor site, morphology, and stage at diagnosis (Klein et al., 2011). Participating
registries are required to provide data collected on primary tumor site, tumor
morphology, type of treatment, and follow-up for survival status (Klein et al., 2011).
NCI staff work directly with registries that are part of the North American
Association of Central Cancer Registries (NAACCR) to support them in confirming that
the data are of high quality and the data can be pooled to obtain national estimates (Klein
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et al., 2011). The NCI personnel accountable for supervising the SEER database also act
as liaisons with registries and other organizations involved with cancer surveillance
(Klein et al., 2011).
In the early part of 1973, the SEER database began collecting statistics on cancer
cases in Connecticut, Hawaii, Iowa, New Mexico, and Utah, along with the metropolitan
areas of Detroit and San Francisco-Oakland (Klein et al., 2011). The metropolitan area of
Atlanta and the 13 counties in the Seattle-Puget Sound areas were added to the database
from 1974 to 1975 (Klein et al., 2011). In 1978, 10 predominantly African American
counties in Georgia were added, and American Indians residing in Arizona were added in
1980. According to SEER, the following three geographical areas participated in the
SEER program prior to 1990: New Orleans, Louisiana (1974-1977, rejoined 2001); New
Jersey (1979-1989, rejoined 2001); and Puerto Rico (1973-1989).
The NCI receives financial support from the government, allowing it to collect
information on cancer cases, including Alaska Native populations (Klein et al., 2011). In
1992, expansion of the SEER database saw the inclusion of minority populations,
particularly Hispanic Americans, through the addition of Los Angeles County and four
counties in the San Jose-Monterey area south of San Francisco (Klein et al., 2011). In
2001, thanks to the availability of funding, SEER database coverage was expanded to
Kentucky, the remaining counties in California (Greater California), New Jersey, and
Louisiana (Klein et al., 2011). The SEER database identifies the 17 national registries
that their case data originate.
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Cancer data at the state level are confidential and protected by legislative efforts
(Klein et al., 2011). These efforts are very specific as to whom cancer information is
reported to, how it is reported, and the procedure for accessing it (Klein et al., 2011;
SEER, n.d.b). There is no identifying information on any SEER data, and permission is
required before access to the data can be obtained.
Data Collection and Analysis
I used archival data from 2011 to 2013 obtained from the SEER database. The
data were extracted manually with the help of SEER professionals and analyzed using
SPSS v.23. The benefit of using the SEER data set is that it is a comparatively
inexpensive way to obtain national data specifically on cancer. One benefit of using SPSS
v.23 is its huge data set capacity and capability to analyze the data statistically. MBC
cases were dichotomized to the United States based on place of residence identified at
time of diagnosis. The study focused on three components (i.e., grade of cancer at
diagnosis, age, and mastectomy) to better define regional differences.
Inclusion criteria were all MBC cases and all ages reported to the SEER database
between 2011 and 2013. The stage at diagnosis has been provided to or recorded by
SEER since 1975. Information about tumor size has been available only since 1988.
Hence, the SEER database was examined for all MC cases diagnosed from 2011 to 2013
so that data on stage and tumor size could be captured for all cases. Lymph node
involvement was not included as a variable in the stage of disease definition because it
could have complicated the statistical analysis (Rosenbaum et al., 2004).
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Quality Control and Quality Assurance
The SEER database is recognized as the gold standard for data quality worldwide
(Klein et al., 2011). To ensure the safety and confidentiality of the retrieved data, all
digital information was stored on a home office computer, and Internet access was
protected by a firewall built into the DSL modem and one built into the Windows XP®
operating system. Data and files were backed up daily, and backups were maintained on a
network drive on a server encrypted or protected by the two firewalls. My personal
computer is password secured, and only I have access to the records (Klein et al., 2011).
Threats to Validity
The most recognized limitation regarding the use of secondary data for analysis
is that the data sometimes are collected for purposes that might not align with other
researchers’ investigations (Boslaugh, 2007). Another major disadvantage of using
secondary data is that secondary researchers do not participate in the data collection
process or know how it was conducted, nor do they know of any issues that might have
arisen, such as low response rates or participants lacking an understanding of survey
questions. Secondary researchers might have to find this information through other
sources, such as documentation of the data collection procedures, technical reports, and
publications (Boslaugh, 2007). It is difficult to calculate the approximate number of the
men who were initially enrolled rather than the number reported.
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Ethical Procedures
I received approval from Walden University’s Institutional Review Board (IRB
approval #09-15-15-0185323) to conduct this study. A letter of approval from the
investigators to use their article for research is in the Appendix.
Possible Types and Sources of Information or Data
All RQs and hypotheses were analyzed using logistic regression. Modeling
included all risk factors listed in Chapter 1 and 2, in addition to all demographic
variables.
Protection of Human Subjects
Cancer registry professionals are obligated to protect the confidentiality of cancer
patient information (Klein et al., 2011). Each cancer registry can impose additional
policies regarding how files and documents are handled (Klein et al., 2011; SEER, n.d.d).
Data retrieved from the SEER program are anonymous, so there is no way to extract
additional personal demographic information about any participants, aside from broad
information (such as sex and race) available on the database that can be used for research
purposes (Klein et al., 2011). The data became available to me once I signed the SEER
data use agreement (SEER, n.d.a).
Summary
Chapter 3 explained the methodology used in this quantitative study of
secondary data. Included was information about the rationale for the research design and
approach, the data source and sample, instrumentation, data collection and analysis, IV,
DVs, and RQs. I also discussed quality assurance and the protection of human subjects.
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Chapter 4: Results
Introduction
Chapter 4 briefly reviews the purpose of the study and presents the results of the
analysis of the archival data obtained from the SEER database. The purpose of this study
was to understand the influence of the predictors of age; race; and grade of cancer (I, II,
or III) on the outcome of mastectomy in MBC. The management of MBC has been
generalized more on disease epidemiology, genetics, and survivorship only; thus, there
were insufficient data to support an investigation into psychosocial well-being.
Data Collection
Inadequate resources relevant to time, money, and the number of MBC cases
available prompted the use of archival data from the SEER database to complete the
study. The data were extracted and analyzed using SPSS v.23. To complicate the process,
I could not compare data from 2010 and earlier to data from 2011 onward because of a
change in the methodology of the BRFSS. Prior to 2011, cell phone data were not
included in the BRFSS, making 2013 only the third year that cell phone data were
included in the files. The official Center for Medicare and Medicaid Services (2012)
weighting schematic was different prior to 2011, so I did not combine data from 2011
forward with data from 2010 and earlier. The estimates obtained from using the weights
for landline and cellphone interviews were not comparable to 2010 and earlier and were
not compared or added to current trend graphs.
I used the SEER database to obtain data from 2011 to 2013 about men diagnosed
with breast cancer. SEER collects SES data such as education or family income on a
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national level, but not on an individual level (SEER, 2016). The average reported age of
MBC cases was 69 years of age. The IVs of this study were age; race; and grade of cancer
(I, II, or III). The DV was mastectomy.
Setting and Sample
I analyzed SEER data from 2011 to 2013 on male patients diagnosed with breast
cancer. These data comprised the sample. To be eligible to be in the study, the SEER data
had to reflect the following criteria: (a) males 18 years of age and older with breast
cancer, (b) United States as the country of residence, (c) age at diagnosis, (d) year of
diagnosis: 2011-2013 inclusive, (e) tumor size, (f) all races/ethnicities reported in the
SEER database, (g) stage of cancer at diagnosis, and (h) mastectomy.
Sample Characteristics
I obtained 2011-2013 SEER data from 427 MBC patients. The number of cases in
parentheses was extracted from the database based on age group: 35-39 (n = 6), 40-49
(n = 18), 45-49 (n = 29), 50-54 (n = 26), 55-59 (n = 46), 60-64 (n = 62), 65-69 (n = 84),
70-74 (n = 59), 75-79 (n = 29), 80-84 (n = 33) and 85 and older (n = 35). The average
reported age of the participant was 65 to 69 years. As seen in Table 3, data were retrieved
for 73 Black men (17%), 335 White men (78%), and 16 Other (4%). I completed the
analysis based on MBC patients, with the greatest reported number in terms of age was
84 men between 65 years and 69 years (19.6%). Table 4 further reports mastectomy by
race, so the total number of Black mastectomy cases was 20 (17%), White was 89 (77%),
Other was 6 (5%), and Unknown was 1 (0.9%), giving a total 116 cases of mastectomy
for MBC.
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Table 3
Sample Characteristics for Age and Race MBC SEER Data 2011-2013
Age
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
Total

No. of cases extracted from data

Black

White

6
18
29
26
46
62
84
59
29
33
35
427

1
3
6
5
8
14
17
7
4
4
2
73

Other
5
14
21
20
36
47
65
49
24
28
33
335

0
1
2
1
2
1
2
3
1
3
0
16

Table 4
MBC Mastectomy Cases by Race 2011-2013
Age
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
Total

MBC
6
18
29
26
46
62
84
59
29
33
35
427

Mastectomy total

Mastectomy
Black
White
2
2
1
2
4
5
1
3

116

20

2
4
5
5
11
14
17
12
4
10
5
89

Other

Unknown

1
2
1
1

1

1

6

1

Table 5 shows the increase in the number of MBC cases by year reported by the
17 cancer registries across all U.S. states except Texas. The number was 130 in 2011, 137
in 2012, and 159 in 2013. Of these 427 cases, 55 had a diagnosis of Grade I cancer, 190
had a diagnosis of Grade II cancer, and 182 had a diagnosis of Grade III cancer. Of the
total for all 3 years, 116 men had undergone mastectomy.
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Table 5
MBC Cases by Year: 2011-2013 SEER Data
2011
2012
2013
130
137
160
Note. One case had Grade IV cancer

Grade I
55

Grade II
190

Grade III
182

Mastectomy
116

The IVs of this study were age; race (Black, White, and Other); and grade of
cancer (I, II, or III) in the United States. The DV was mastectomy. Logistic regression
analyses were based on chi-square analyses conducted to test significance for all
hypotheses; correlations to rule out multicollinearity were run among all IVs having a
Pearson’s r ≤ .000. Most relationships were statistically insignificant because alpha was
≥ .05).
Regression analysis was conducted on White MBC patients according to age
group; the mean age was 65 years. Mastectomy information on White MBC patients is
displayed in Table 6 by categorical group 35 to 85 years: 35 to 39 years (n = 2, 0.5%); 40
to 44 years (n = 6, 1.4%); 45 to 49 years (n = 8, 1.9%); 50 to 54 years (n = 8, 1.9%); 55 to
59 years (n = 14, 3.3%); 60 to 64 years (n = 19, 4.4%); 65 to 69 years (n = 23, 5.5%); 70
to 74 years ( n = 13, 3.0%); 75 to 79 years (n = 4, 0.9%); 80 to 84 years (n = 14, 3.3%);
and 85 and older (n = 6, 1.4%). For the current study, results showed that the prevalence
of mastectomy among men with MBC increased significantly among White patients, less
among Black patients, and the least for Other.
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Table 6
White MBC Patients by Age Group
Valid N
AGE * 35-39
AGE * 40-44
AGE * 45-49
AGE * 50-54
AGE * 55-59
AGE * 60-64
AGE * 65-69
AGE * 70-74
AGE * 75-79
AGE * 80-84
AGE * 85+
N = 427

Missing
2
6
8
8
14
19
23
13
4
14
6

%

n
0.5%
1.4%
1.9%
1.9%
3.3%
4.4%
5.4%
3.0%
0.9%
3.3%
1.4%

425
421
419
419
413
408
404
414
423
413
421

%
99.5%
98.6%
98.1%
98.1%
96.7%
95.6%
94.6%
97.0%
99.1%
96.7%
98.6%

N
427
427
427
427
427
427
427
427
427
427
427

%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%

Initially, I planned to conduct hierarchical multiple linear regression analyses only
(see Tables 7, 8, 9, 10, 11, & 12). For multiple linear regression, R, or the coefficient of
determination, is used as a measure of effect size, namely, the adjusted R2. Although
results for the multiple linear regression showed that the IVs of Age and White race were
significant, the effect sizes (adj. R2) for all models were undetectable, indicating no
meaningful or practical significance. The data were then analyzed using hierarchical
logistic regression, with the DVs being treated as dichotomous. I reported only logistic
regression analysis results. Logistic regression, particularly binary logistic regression, is
used when the DV is dichotomous.
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Table 7
Logistic Regression Analysis for the IVs
Model

Unstandardized
coefficients
B
SE
Age
0.873
0.076
Grade I
-7.47E-15
0.130
Grade II
4.79E-14
0.090
Grade III
-6.54E-14
0.097
Black
-4.04E-14
0.097
White
1.27E-01
0.031
Other
3.04E-15
0.109
Note. DV was mastectomy

Standardized
coefficients
Beta
0.780
0.000
0.000
0.000
0.000
0.118
0.000

t

Sig

11.438
0.000
0.000
0.000
0.000
4.052
0.000

0.000
1.000
1.000
1.000
1.000
0.000
1.000

95% CI for B
Lower bound
0.723
-.256
-.176
-.191
-.191
-.066
-0.215

Upper bound
1.022
0.256
0.176
0.191
0.191
0.189
0.215

Table 8
Chi-Square Tests for Age

Pearson chi-square
Continuity correctionb
Likelihood ratio
Fisher’s exact test
Linear-by-linear association
a.
DVs
b.
Correlation

Value
28.718a
27.153
46.120

df
1
1
1

Asymptotic Sig.
(2-sided)
.000
.000
.000

28.651

1

.000

Exact Sig.
(2-sided)

Exact Sig.
(1-sided)

.000

.000

Table 9
Age and Mastectomy
B
Step 0
Constant
.986
Note. Variable in equation is age.

SE
.109

Wald
82.172

df
1

Table 10
Omnibus Tests of Model Coefficients Age
Step 1

Step
Block
Model

Chi-square
286.785
286.785
286.785

df
1
1
1

Sig.
.000
.000
.000

Sig.
.000

Exp(B)
2.681
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Table 11
Logistic Regression: IV of Mastectomy and IV of White Race
B

SE

Step
1a

WHITE
-20.567
4190.415
(1)
Constant 21.203
4190.415
a. Variable(s) entered on Step 1: WHITE.

Wald

df

Sig.

Exp(B)

.000

1

.996

.000

.000

1

.996

1615476258.503

95% CI for
EXP(B)
Lower Upper
.000

Table 12
Chi-Square
Step 1

White
Step
Block
Model

Chi-square
67.288
67.288
67.288

df
1
1
1

Sig.
.000
.000
.000

Independent Variables
Age. RQ1: How will age impact knowledge related to mastectomy in MBC? Null
Hypothesis 1 is rejected because p ≤ .05, meaning that it was statistically significant
(β =.780, t = 11.438 [see Table 7]; (p < .05); chi-square test p = .000 [see Table 8 and
Table 10])). Therefore, Alternative Hypothesis 1 is accepted.
Race. RQ2: How will race account for MBC in relation with mastectomy?
Analysis was as follows: Black (β = 0.000, t = .000 [see Table 7]; p = 1.000 (p > .05);
chi-square test [see Table 8]); White (β = 0.118, t = 4.052 [see Table 7; (p = .000) and (p
≤ .05) therefore statistically significant; chi-square test [see Table 12]); and for Other race
(β = 0.00; t = .000 [see Table 7]; (p >.05), Other race is statistically insignificant (p =
1.000; p > .05). Data for White were statistically significant (p < .05), so Null Hypothesis
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2 is rejected, and Alternative Hypothesis 2 is accepted. The data for Black and Other
cases were insignificant (p =1.000; p > .05), which was greater than
(p > .05). Therefore, the null hypothesis is accepted, and the alternative hypothesis
rejected for Black and Other race categories; the null hypothesis is rejected for White
race only.
Grade. RQ3: Is there a predictive relationship between mastectomy and Grade I,
II, or III cancer in MBC? Results shown on Table 7 were as follows: Grade I
(β = 0.000, t = .000, p = 1.000); Grade II (β = 0.000, t = .000, p > 1.000); and Grade III (β
= 0.000, t = .000, p > 1.000). All three grades were statistically insignificant (p < .05).
Therefore, Null Hypothesis 3 is accepted, and Alternative Hypothesis 3 is rejected. Data
from 116 of the 427 MBC patients (27.1%) reported having been treated with
mastectomy at a later grade (II or III) of cancer; 311 (72.8%) reported receiving hormone
therapy, but no surgery (see Table 7).
Dependent Variable of Mastectomy
As already mentioned, 116 (27.1%) of the 427 MBC cases reported having
mastectomy at a later stage of cancer, whereas 311 (72.8%) reported receiving hormone
therapy (see Table 13). In Table 9, mastectomy correlated at a significant level (p ≤ .000)
on age, and significant (p < .05; p = .000); chi-square test [see Table 12]) on race, thus
displaying statistical significance and disproving the null hypotheses for all IVs.

64
Table 13
Mastectomy as the DV
Classification table
Observed

Step 0

Mastectomy

Yes
No

Predicted
Mastectomy
Yes
No
0
116
0
311

% correct

Overall percentage
a. Constant was included in the model.
b. Cut value was .500

.0
100.0
72.8

Logistic Regression Analysis
Table 7 showed the logistic regression analysis that was conducted; the p-value of
< .05 was considered statistically significant. Table 7 showed the logistic regression of IV
and DV. Age β = .780, standard error of 0.076 with a t value of 11.438 and age statistical
significance (p < .05; chi-square test p = .000), the 95% interval for B lower bound was
0.723 and upper bound was 1.022. For race, Black (β = 0.000, t = .000, statistical
insignificance (p > .05; p = 1.000 chi-square test) t = .000, 95% lower -.191 and upper
.191. White (β = 0.118 and t = 4.052, (p < .05; p = .000 chi-square) 95% interval lower 0.066 and upper 0.189. Grade I t = 0.000 sig 1.000, which was statistically insignificant p
≥ .05; 95% interval lower -0.256 and upper 0.256. Grade II, t = 0.000 (p = 1.000 p > .05)
statistically insignificant, 95% interval lower -.176 and upper .176. Grade III, t = 0.000,
(p = 1.000 p > .05); 95% interval lower -.191 and upper .191.
Statistical Analysis
SPSS v.23 was used to compute the results. The first stage of the analysis
involved descriptive statistics of the preliminary associations among age; race; and grade
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of cancer (I, II, or III). However, the DV of mastectomy outcome was tested against the
three IVs using independent t tests for the dichotomous variables and Pearson’s productmoment correlations for the continuous variables. For independent t tests, all were
significant (p = .000; p < .05). Levine’s test for equality of variances was studied to
account for the possibility of an unequal variance of samples. For example, Table 14
shows F = 121.271 and that the values were statistically significant (p = .000; p < .05).
Separate variance estimates also were reported. Table 14 is a model summary of logistic
regression, where R is .818a, F = 121.271, df = 7, and sig F change p = .000.
Table 14
Model Summary IV

R

Adj. R

2

Model summary
SE of the
estimate
R2 change

Change statistics
F
df1
df2
Sig. F
change
change
1
.818a
.670
.664
.258
.670 121.271
7
419
.000
a. Predictors: (Constant), OTHER, WHITE, AGE, GRADE I, GRADE II, GRADE III, BLACK
Model

R

2

In conclusion, drawn from the MBC study, p > .05 because the output read
p 1.00 statistically, insignificant predictors for Grade I, Grade II, Grade III used to test
against mastectomy. However, measures of age and race were statistically significant in
the White population of MBC, where β = .118, t = 4.052; (p = .000; p < .05) and age
β =. 780 t = 11.438 and (p = .000, showing is p < .05).
Summary
Chapter 4 presented the results of the analysis of archival data from 2011 to 2013
obtained from the SEER database to examine the prevalence of MBC in terms of age,
race, and grade of cancer as the IVs and mastectomy outcome as the DV. A total of 427
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cases from SEER archival data were examined. Results of the study will add to
knowledge of MBC in United States. Chapter 5 summarizes and interprets the findings
and offers recommendations for future research.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this study was to understand the influence of the predictors of age;
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC.
Logistic regression analyses were based on chi-square analyses conducted to test
significance for all hypotheses, all IVs significantly predicted, and added to the predictive
variables and were all related to mastectomy. Prior to logistic regression analyses,
correlations to rule out multicollinearity were run among all IVs in the analysis, which
successfully produced a Pearson’s r < .000.
Interpretation of the Findings
I extracted archival data dating from 2011 to 2013 from the SEER database to
study the relationship between the IVs of age, race, and grade of cancer, and the DV of
mastectomy among men diagnosed with MBC. Breast cancer has a range of specific
stressors that can threaten men’s emotional well-being after mastectomy. Examples of
these postsurgery stressors are concerns about masculinity and the sense of isolation
associated with a lack of support and not knowing where to seek for information (Brain et
al., 2006). A general lack of awareness and information can inhibit the support needed to
deal with MBC. Sociopsychological factors affecting well-being that were not included in
this study but might be considered in future studies are the use of avoidance coping
strategies, fear and uncertainty about the future, altered body image, and unmet
information needs in relation to breast cancer and mastectomy. A larger study might help
to identify the impact of these variables on the psychosocial well-being of men
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experiencing various grades of MBC as well as stages of MBC that have yet to be
studied.
There have been many studies of age, race, grades of cancer, and coping in regard
to women who have been diagnosed with breast cancer, but few studies have focused on
male cancer patients. Although past results have confirmed that age and race can predict
poor adjustment to breast cancer (Brain et al., 2006), further research is needed to explore
the relationship of the IVs of age, race, and grade of cancer to the DV of mastectomy
experienced over the course of breast cancer.
Limitations of the Study
Because I analyzed secondary data and had no involvement in the initial
collection of primary data, I was unable to follow up with or reach out to the participants
directly, making the generalizability of the findings unclear. Another disadvantage of
using archival data was that I did not participate in the data collection process, making it
difficult to calculate the approximate number of the men who were initially enrolled
rather than the number who were reported in the SEER database. The archival data were
limited because the questions were not evenly asked during the 2011-2013 period in most
states.
Source of Bias
Sources of bias were very limited, but the initial questions did not indicate
whether the MBC archived data were obtained only from men because there was no
indication of transgender issues reported for MBC by the SEER submitters. Questions
were not evenly asked in all states during the 2011-2013 data collection period. In
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addition, the psychosocial unavailability in the database created a setback during the
analysis, leading to challenges while extracting the data for this study.
Reliability and Validity
Responses to the questionnaire submitted by the original investigators to the
SEER database through the BRFSS were checked for reliability and validity by doublechecking the data source for accuracy and source confirmation. Internal validity also
presented additional limitations because these were secondary data. Extraction was
meticulously double-checked from the original data for errors, so the external validity
was not a challenge because of the large sample size of the study from the SEER
database.
Recommendations for Future Research
Future researchers should focus on assessing the specific educational and social
needs of men with breast cancer, along with their experiences as patients in the medical
community and as members of society. Cooperative groups could be formed throughout
the United States and other countries to provide information about the impact of cultural
diversity on the experience of MBC. This information could give counselors the
opportunity to better tailor counseling sessions to meet the unique needs of men with
breast cancer. It is important to recognize the individuality of each MBC patient,
regardless of age and race, and the shared experiences that men with breast cancer
experience. The challenge is to incorporate knowledge of these shared experiences with
each man’s unique personality and life experience to devise health care plans that will
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enable these men to make the best decision not only for their families but also for
themselves.
Implications for Positive Social Change
This study emphasized the need for increased awareness and information about
MBC. Having a disease that affects predominantly women can threaten a man’s sense of
masculinity and engender feelings of isolation. Men might benefit from receiving
information early in the referral process about: treatment options, side effects, symptoms,
survival rates, cancer reoccurrence, and the potential impact on quality of life and body
image after undergoing mastectomy.
Health care professionals play an important role in providing information and
support to men with breast cancer about the availability of formal support networks.
Practical suggestions for improving information and awareness include disseminating
leaflets with information on MBC and a photograph of a critical male mastectomy,
supporting local matching schemes and telephone help-lines, and raising public awareness
through the media. Insurance companies should provide men and women with annual
mammograms. This preemptive measure could lead to more acceptance of men having
mammograms and much earlier detection of MBC.
Men might be less likely than women to disclose distress and seek help, so it is
possible that health care providers might be underestimating the psychosocial impact of
breast cancer on men. Screening distress is essential so that men who might benefit from
additional emotional support can be identified early in the referral process. General
screening tools such as the Hospital Anxiety and Depression Scale, which asks about
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anxiety and depression, might underestimate the prevalence of distress in men with breast
cancer, so disease-specific measures such as the Impact of Event Scale, another
questionnaire that asks distress questions, should be used in combination with the
Hospital Anxiety and Depression Scale to give future researchers easy access to the data.
Conclusion
The present study adds knowledge to the literature by using archival data from the
SEER database to understand the influence of the predictors of age; race; and grade of
cancer (I, II, or III) on the outcome of mastectomy in MBC. However, future research is
needed to expand the present findings. The lack of dedicated resources and research
focusing on MBC patients in the United States highlights the need for psychosocial
support such as counseling services for men who have breast cancer. The most critical
social change is to ensure the timely dissemination of MBC to reach men, regardless of
age or location.
Discussion
Much of the research on MBC has been extrapolated from research on the
incidence of female breast cancer, likely because of the infrequent incidence of MBC.
The purpose of this study was to understand the influence of the predictors of age; race;
and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. Based on the
theory of projection, a concern would be that these feelings could exacerbate the shame
and confusion that men with MBC experience, particularly because breast cancer is
considered a cancer specific to women. Men with MBC feel there has been a lack of
educational aids dedicated to the needs of men. Typically, men present in the denial
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stage, questioning their sexual orientation, masculinity, and belief in God regarding their
diagnosis of breast cancer.
A mastectomy is considered as making significant alterations to the male selfimage and having the potential to impact male sexuality. Mastectomy scars are
concerning to men in that they feel that society will consider them as feminine. This
study examined how age; race; and grade of cancer (I, II and III) influenced mastectomy
following a diagnosis of MBC.
Age was a psychosociological predicator variable. As a construct in the social
determinants of health framework, age was statistically significant in the White
population of men diagnosed with MBC. Age also determined how well the MBC
patients handled anxiety in terms of worry and fear whenever the symptoms became
more severe or when undergoing testing to determine whether the cancer had progressed.
The younger MBC patients were the most concerned about body image.
Some of the most common fears for all ages of MBC patients studied were the
painful procedures associated with the disease and such side effects as hair loss, nausea,
fatigue, and pain. Younger MBC patients worried about disruptions to their daily lives
that led to fear and anxiety because of their inability to work. Older MBC patients who
had already reached retirement worried less.
Race is another construct in the social determinants of health framework. Racial
disparities existed in the management of MBC in terms early diagnosis and access to
health care. Race also was statistically significant in the White population of MBC. Most
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White patients were insured, but Black patients were underinsured because of the lack of
social support, poor employment prospects, and lack of resources.
Adding to the social determinants of health framework, grade of cancer refers to
the aggressiveness of its management. Grade I cancer is a low grade; in Grade II cancer,
cells become differentiated and require treatment; and in Grade III cancer, the cells grow
and spread rapidly. MBC patients in this study who were at this latter stage reported
frustration, emotional distress, and the inability to cope. Grade I denial in breast cancer
can lead to deregulation of the immune system and results in long-term physical and
emotional problems that cause distress. Many patients with Grade 1 cancer who are
waiting for MBC test results experience tremendous distress.
Grade II is another construct of the social determinants of health framework.
MBC patients generally seek a mastectomy during Grade II, and depending on the
relationships that they have with partners or caregivers, they report body image issues in
an effort to seek emotional help to deal with the disease. Caregivers or partners might
offer advice about treatment options such as breast-conserving surgery or reconstructive
surgery, to enhance body image caused by mastectomy (Rab, 2012).
Grade III is another construct in the social determinants of health framework.
MBC patients with this grade of cancer need help coping with the effects of
chemotherapy on MBC. Most patients with Grade III MBC also seek mastectomy. The
MBC patients in my study reported very poor physical and emotional QOL when coping
with the treatment regimen. The side effects of antiestrogen during treatment can include
weight gain, fatigue, and depression; mastectomy can lead to worry about body image

74
(Rudy & Winer, 2013). Because of the side effects of treatment, regardless of the grade
of cancer, men with MBC need emotional support (Brain et al., 2006).
Psychosocial comorbidities also had a negative effect on the emotions of the
patients with MBC in my study. Feelings of uncertainty gave rise to feelings of
hopelessness, and the absence of social networks was noted as leading to decreased
survival rates and a rapid increase in the course of the disease. The prediction of
psychosocial variables needs to be tested in future research so that practitioners can help
MBC patients to manage the disease. Researchers also might want to consider
investigating the understudied general cancer-related distress, anxiety, and depressive
symptoms and depression experienced by patients with MBC during chemotherapy.
MBC patients who have Grade I, Grade II, or Grade III MBC who have undergone
mastectomy also have body image issues. Unfortunately, none of this information was
reported in the SEER database.
In addition, future researchers should encourage MBC patients to discuss the
cancer experience with others in order to facilitate the cognitive processing required for
positive reframing, a finding with important implications for psychosocial interventions.
Finding literature related to MBC that focused on age; race; and grade of cancer (I, II,
and III) was challenging. Men who are struggling with MBC are withdrawn and reluctant
to participate in research. Therefore, I recommend that financial incentives be provided to
men with MBC to encourage their participation in future MBC-focused research.
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Summary
Finally, the interpretation of the findings requires caution because the study was
conducted with archival data. Measurement issues pertaining to the validity and
reliability of the instruments used were clarified by SEER personnel, who stated that the
archival data were validated prior to submission. Evaluating age; race; and grade of
cancer (I, II, or III) in relation to mastectomy in MBC continues to limit investigations
within cross-sectional or longitudinal frameworks.
In addition, this study went through changes, as with any correlational research,
primarily because of the rarity of MBC and difficulty finding data in the SEER database
addressing the variables. Future investigators might consider giving more attention
during the early stages to defining a construct in order to avert the same problems. Social
change implications should include the provision of group counseling, emotional support,
and financial support to benefit the psychosocial well-being of patients with MBC.
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